The dawn of phage therapy

被引:95
作者
Rehman, Sana [1 ]
Ali, Zahid [1 ]
Khan, Momna [1 ]
Bostan, Nazish [1 ]
Naseem, Saadia [1 ]
机构
[1] COMSATS Univ Islamabad, Dept Biosci, Islamabad, Pakistan
关键词
bacteriophages; development; endolysin; therapy; use; RESISTANT STAPHYLOCOCCUS-AUREUS; JUVENILE SEA-CUCUMBER; CYCLIC GMP-AMP; ESCHERICHIA-COLI; IN-VITRO; BACTERIOPHAGE APPLICATION; ANTIBIOTIC-RESISTANCE; IMMUNE-RESPONSE; INFECTION; LYSIN;
D O I
10.1002/rmv.2041
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Bacteriophages or phages, being the most abundant entities on earth, represent a potential solution to a diverse range of problems. Phages are successful antibacterial agents whose use in therapeutics was hindered by the discovery of antibiotics. Eventually, because of the development and spread of antibiotic resistance among most bacterial species, interest in phage as therapeutic entities has returned, because their noninfectious nature to humans should make them safe for human nanomedicine. This review highlights the most recent advances and progress in phage therapy and bacterial hosts against which phage research is currently being conducted with respect to food, human, and marine pathogens. Bacterial immunity against phages and tactics of phage revenge to defeat bacterial defense systems are also summarized. We have also discussed approved phage-based products (whole phage-based products and phage proteins) and shed light on their influence on the eukaryotic host with respect to host safety and induction of immune response against phage preparations. Moreover, creation of phages with desirable qualities and their uses in cancer treatment, vaccine production, and other therapies are also reviewed to bring together evidence from the scientific literature about the potentials and possible utility of phage and phage encoded proteins in the field of therapeutics and industrial biotechnology.
引用
收藏
页数:16
相关论文
共 155 条
[11]   Phage Therapy in the Era of Synthetic Biology [J].
Barbu, E. Magda ;
Cady, Kyle C. ;
Hubby, Bolyn .
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2016, 8 (10)
[12]  
BARFOOT R, 1989, IMMUNOLOGY, V68, P233
[13]   A bacteriophages journey through the human body [J].
Barr, Jeremy J. .
IMMUNOLOGICAL REVIEWS, 2017, 279 (01) :106-122
[14]   Antibiotic resistance in the food supply chain: where can sequencing and metagenomics aid risk assessment? [J].
Bengtsson-Palme, Johan .
CURRENT OPINION IN FOOD SCIENCE, 2017, 14 :66-71
[15]  
Bogovazova G G, 1992, Zh Mikrobiol Epidemiol Immunobiol, P30
[16]  
BOGOVAZOVA GG, 1991, ZH MIKROB EPID IMMUN, P5
[17]   Bacteriophage genes that inactivate the CRISPR/Cas bacterial immune system [J].
Bondy-Denomy, Joe ;
Pawluk, April ;
Maxwell, Karen L. ;
Davidson, Alan R. .
NATURE, 2013, 493 (7432) :429-U181
[18]  
Boyacioglu Olcay, 2013, Bacteriophage, V3, pe24620
[19]   Engineered Endolysin-Based "Artilysins" To Combat Multidrug-Resistant Gram-Negative Pathogens [J].
Briers, Yves ;
Walmagh, Maarten ;
Van Puyenbroeck, Victor ;
Cornelissen, Anneleen ;
Cenens, William ;
Aertsen, Abram ;
Oliveira, Hugo ;
Azeredo, Joana ;
Verween, Gunther ;
Pirnay, Jean-Paul ;
Miller, Stefan ;
Volckaert, Guido ;
Lavigne, Rob .
MBIO, 2014, 5 (04)
[20]   Human volunteers receiving Escherichia coli phage T4 orally:: a safety test of phage therapy [J].
Bruttin, A ;
Brüssow, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (07) :2874-2878